About ArunA Bio
ArunA Bio is a company based in Athens (United States) founded in 2017. ArunA Bio has raised $38.51 million across 13 funding rounds from investors including HHS, NIH SBIR/STTR and Eshelman Ventures. ArunA Bio offers products and services including AB126 and Neural Exosome Platform. ArunA Bio operates in a competitive market with competitors including BioLife Solutions, Ribometrix, ReNAgade, RoosterBio and Creyon Bio, among others.
- Headquarter Athens, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aruna Bio, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$38.51 M (USD)
in 13 rounds
-
Latest Funding Round
$679.41 K (USD), Grant
Jun 01, 2022
-
Investors
HHS
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ArunA Bio
ArunA Bio offers a comprehensive portfolio of products and services, including AB126 and Neural Exosome Platform.
Exosome that reduces neuro-inflammation and promotes neuro-protection.
Platform enabling access across the blood-brain barrier for treatments.
People of ArunA Bio
Unlock access to complete
Unlock access to complete
Funding Insights of ArunA Bio
ArunA Bio has successfully raised a total of $38.51M across 13 strategic funding rounds. The most recent funding activity was a Grant round of $679.41 thousand completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ArunA Bio
ArunA Bio has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NIH SBIR/STTR and Eshelman Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for ArunA Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ArunA Bio
Investment portfolio details for ArunA Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ArunA Bio
Detailed financials for ArunA Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aruna Bio Comparisons
Peer comparison for ArunA Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ArunA Bio
ArunA Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioLife Solutions, Ribometrix, ReNAgade, RoosterBio and Creyon Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| Locked | Locked | Locked |
RNA-targeted drug discovery platform using three-dimensional structural analysis is provided.
|
|
| Locked | Locked | Locked |
RNA-based medicines are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| Locked | Locked | Locked |
Oligonucleotide-based drug development platform is provided using AI models.
|
|
| Locked | Locked | Locked |
Serum-free cell culture media is supplied to biopharmaceutical industries.
|
Detailed competitors of ArunA Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aruna Bio
Complete news archive for ArunA Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ArunA Bio
ArunA Bio was founded in 2017.
ArunA Bio is headquartered in Athens, United States.
ArunA Bio is a funded company, having raised a total of $38.51M across 13 funding rounds to date.
Founded in 2017 and based in Athens, United States, ArunA Bio operates in the biotechnology sector. A neural exosome platform is utilized to create therapeutics that cross the blood-brain barrier. Anti-inflammatory, self-repair, and protective mechanisms in the body are enhanced to address neurodegenerative disorders. The lead candidate, AB126, targets stroke, Parkinsons disease, and multiple sclerosis.
ArunA Bio's top competitors include FabricNano, RoosterBio and BioLife Solutions.
ArunA Bio offers AB126 and Neural Exosome Platform.
ArunA Bio has 3 investors. Key investors include HHS, NIH SBIR/STTR, and Eshelman Ventures.